F. Cairnduff
-
- Photodynamic Therapy Research Studies 9
- Sarcoma Diagnosis and Treatment 1
- Dermatology top 5%
-
- Breast Cancer Treatment Studies 2
- Ophthalmology top 5%
- Ocular Oncology and Treatments 5
- Epidemiology top 10%
- Nonmelanoma Skin Cancer Studies 3
-
- Nanoplatforms for cancer theranostics 3
-
- Angiogenesis and VEGF in Cancer 2
-
- Vascular Tumors and Angiosarcomas 1
F. Cairnduff
14 papers receiving 876 citations
Peers
Comparison fields: 5 of 82
- Pulmonary and Respiratory Medicine 529
- Dermatology 136
- Cancer Research 140
- Ophthalmology 72
- Epidemiology 271
Countries citing papers authored by F. Cairnduff
This map shows the geographic impact of F. Cairnduff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Cairnduff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Cairnduff more than expected).
Fields of papers citing papers by F. Cairnduff
This network shows the impact of papers produced by F. Cairnduff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Cairnduff. The network helps show where F. Cairnduff may publish in the future.
Co-authorship network
The 25 scholars most cited alongside F. Cairnduff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2002 | 63 | |
| 2 | Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. | 2000 | 286 |
| 3 | 2000 | 78 | |
| 4 | 1995 | 58 | |
| 5 | 1995 | 16 | |
| 6 | 1995 | 6 | |
| 7 | 1995 | 3 | |
| 8 | 1994 | 296 | |
| 9 | 1994 | 39 | |
| 10 | 1994 | 14 | |
| 11 | Anti-endothelial antibodies in the sera of cancer patients―a possible indicator of treatment-induced tissue damage | 1992 | 1 |
| 12 | 1991 | 19 | |
| 13 | Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine). | 1989 | 10 |
| 14 | 1987 | 32 |
About F. Cairnduff
F. Cairnduff is a scholar working on Ophthalmology, Pulmonary and Respiratory Medicine, Oncology, Cancer Research and Dermatology, having authored 14 papers that have together received 921 indexed citations. Recurring topics across this work include Photodynamic Therapy Research Studies (9 papers), Ocular Oncology and Treatments (5 papers), Nonmelanoma Skin Cancer Studies (3 papers), Nanoplatforms for cancer theranostics (3 papers), Breast Cancer Treatment Studies (2 papers), Angiogenesis and VEGF in Cancer (2 papers), Vascular Tumors and Angiosarcomas (1 paper) and Sarcoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (529 citations), Dermatology (136 citations), Cancer Research (140 citations), Ophthalmology (72 citations) and Epidemiology (271 citations). F. Cairnduff has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include SB Brown, David Roberts, David J. Roberts, Stanley B. Brown, M A Forbes, Mark Lansdown, Roy Bicknell, Ken MacLennan, Jacqui Adams and James J. Walker. Their work appears in journals such as International Journal of Oncology, British Journal of Cancer, Oncology Reports, British Journal of Radiology and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.